PMID- 35890217
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220731
IS  - 1999-4923 (Print)
IS  - 1999-4923 (Electronic)
IS  - 1999-4923 (Linking)
VI  - 14
IP  - 7
DP  - 2022 Jun 22
TI  - Stimuli-Responsive Gold Nanocages for Cancer Diagnosis and Treatment.
LID - 10.3390/pharmaceutics14071321 [doi]
LID - 1321
AB  - With advances in nanotechnology, various new drug delivery systems (DDSs) have 
      emerged and played a key role in the diagnosis and treatment of cancers. Over the 
      last two decades, gold nanocages (AuNCs) have been attracting considerable 
      attention because of their outstanding properties. This review summarizes current 
      advancements in endogenous, exogenous, and dual/multi-stimuli responsive AuNCs in 
      drug delivery. This review focuses on the properties, clinical translation 
      potential, and limitations of stimuli-responsive AuNCs for cancer diagnosis and 
      treatment.
FAU - Li, Chunming
AU  - Li C
AD  - Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, 
      Chongqing 400030, China.
FAU - Zhao, Tengyue
AU  - Zhao T
AD  - School of Pharmaceutical Sciences, Zhengzhou University, No. 100 Kexue Avenue, 
      Zhengzhou 450001, China.
FAU - Li, Lixian
AU  - Li L
AD  - Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, 
      Chongqing 400030, China.
FAU - Hu, Xiaogang
AU  - Hu X
AD  - Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, 
      Chongqing 400030, China.
FAU - Li, Chao
AU  - Li C
AD  - Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, 
      Chongqing 400030, China.
FAU - Chen, Wanyi
AU  - Chen W
AD  - Department of Pharmacy, Chongqing University Cancer Hospital, No. 181 Hanyu Road, 
      Chongqing 400030, China.
FAU - Hu, Yurong
AU  - Hu Y
AUID- ORCID: 0000-0002-0354-7939
AD  - School of Pharmaceutical Sciences, Zhengzhou University, No. 100 Kexue Avenue, 
      Zhengzhou 450001, China.
LA  - eng
GR  - cstc2019jcyj-msxmX0035/the Natural Science Foundation of Chongqing, China/
GR  - have no number/the Chongqing Clinical Pharmacy Key Specialties Construction 
      Project/
GR  - 81272563/the National Natural Science Foundation of China/
PT  - Journal Article
PT  - Review
DEP - 20220622
PL  - Switzerland
TA  - Pharmaceutics
JT  - Pharmaceutics
JID - 101534003
PMC - PMC9318695
OTO - NOTNLM
OT  - cancer
OT  - controlled release
OT  - diagnosis
OT  - gold nanocages
OT  - stimuli-responsive
OT  - treatment
COIS- The authors declare no conflict of interest.
EDAT- 2022/07/28 06:00
MHDA- 2022/07/28 06:01
PMCR- 2022/06/22
CRDT- 2022/07/27 01:38
PHST- 2022/05/26 00:00 [received]
PHST- 2022/06/15 00:00 [revised]
PHST- 2022/06/18 00:00 [accepted]
PHST- 2022/07/27 01:38 [entrez]
PHST- 2022/07/28 06:00 [pubmed]
PHST- 2022/07/28 06:01 [medline]
PHST- 2022/06/22 00:00 [pmc-release]
AID - pharmaceutics14071321 [pii]
AID - pharmaceutics-14-01321 [pii]
AID - 10.3390/pharmaceutics14071321 [doi]
PST - epublish
SO  - Pharmaceutics. 2022 Jun 22;14(7):1321. doi: 10.3390/pharmaceutics14071321.